Although EGFR- and Her2-directed therapies have yielded disappointing clinical results to date, recent reports regarding the role of other members of this receptor tyrosine kinase family, such as ErbB3 and ErbB4, in ovarian cancer suggest that new approaches towards targeting the EGFR family merit further exploration. Here, ERBB4 is linked to ovarian carcinoma.